Tesla Inc will build mobile molecular printers to help create the potential COVID-19 vaccine being developed by CureVac in Germany. This was announced on Twitter by general company Elon Musk.
CureVac previously said it was developing the so-called RNA printer, a “revolutionary, transportable platform for the production of mRNA vaccines.” The Epidemic Preparedness Innovation Coalition (CEPI) has committed $ 34 million for this project.
In June, CureVac received permission to conduct the first phase of clinical trials of its own coronavirus vaccine in Germany and Belgium, and 168 people aged 18 to 60 will take part in the tests. The purpose of the research is to determine the optimal dose and evaluate the safety as well as the human immune response to the drug. Vaccine development began in early 2020.